Sérgio Serrano

AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer

Luca Gianni, Gilles Romieu, Sérgio Serrano et al. · Journal of Clinical Oncology · 2013 · 255 citations · Full text

First-line Therapy, Breast Oncology, Medicine +13

Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial

John C. Araujo, Géralyn C. Trudel, Fred Saad et al. · The Lancet Oncology · 2013 · 229 citations · Full text

Double-blind Phase 3, Urology, Genitourinary Cancer +6

MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy

Alexandra Valera, Armando López‐Guillermo, Teresa M. Cardesa‐Salzmann et al. · Haematologica · 2013 · 225 citations · Full text

Immunology, Pathology, Myc Amplifications +16

Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group

Marta Salido, Cristina Baró, David Oscier et al. · Blood · 2010 · 190 citations · Full text

Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer

Federico Rojo, Jetzabel García-Parra, Sandra Zazo et al. · Annals of Oncology · 2011 · 177 citations

Breast Oncology, Poor Overall Survival, Early Breast Cancer +10